GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InDex Pharmaceuticals Holding AB (OSTO:INDEX) » Definitions » 3-Year EPS without NRI Growth Rate

InDex Pharmaceuticals Holding AB (OSTO:INDEX) 3-Year EPS without NRI Growth Rate : 9.10% (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is InDex Pharmaceuticals Holding AB 3-Year EPS without NRI Growth Rate?

InDex Pharmaceuticals Holding AB's EPS without NRI for the three months ended in Mar. 2024 was kr-0.01.

During the past 3 years, the average EPS without NRI Growth Rate was 9.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was 7.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 10 years, the highest 3-Year average EPS without NRI Growth Rate of InDex Pharmaceuticals Holding AB was 25.00% per year. The lowest was -67.20% per year. And the median was 9.10% per year.


Competitive Comparison of InDex Pharmaceuticals Holding AB's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, InDex Pharmaceuticals Holding AB's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InDex Pharmaceuticals Holding AB's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InDex Pharmaceuticals Holding AB's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where InDex Pharmaceuticals Holding AB's 3-Year EPS without NRI Growth Rate falls into.



InDex Pharmaceuticals Holding AB 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


InDex Pharmaceuticals Holding AB  (OSTO:INDEX) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


InDex Pharmaceuticals Holding AB 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of InDex Pharmaceuticals Holding AB's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


InDex Pharmaceuticals Holding AB (OSTO:INDEX) Business Description

Traded in Other Exchanges
N/A
Address
Berzelius vag 13, Solna, SWE, 171 65
InDex Pharmaceuticals Holding AB is a pharmaceutical company focusing on immunological diseases with great medical needs for new treatment options. The company's main asset is the drug candidate cobitolimod, which is being evaluated in the phase III study as a treatment for moderate to severe ulcerative colitis - a disabling, chronic inflammation of the colon. It has also developed a platform of patent-protected substances, so-called DNA-based Immunomodulatory Sequences, with the potential to be used in the treatment of various immunological diseases.

InDex Pharmaceuticals Holding AB (OSTO:INDEX) Headlines

No Headlines